Scholarlink

Objective <p>The study evaluates the clinical relevance of the serum biomarkers Cyfra 21-1 and SCC Ag in patients diagnosed with head and neck carcinoma (HNC).</p> Background <p>Unfortunately, no reliable circulating blood marker for HNC has yet been accepted for application in clinical practice.</p> Methods <p>We retrospectively analyzed serum concentrations of SCC Ag and Cyfra 21-1 in 326 patients, with measurements obtained pre-treatment, post-treatment, during follow-up, and at the time of recurrence.</p> Results <p>We confirmed a significant association between markers and tumour progression. The pre-treatment concentration dropped significantly after therapy in patients who achieved remission. We proposed SCC Ag and Cyfra 21-1 cut-off values of 2.0&#xa0;ng/mL and 3.3&#xa0;ng/mL for the selection of patients with residual disease. In cases of tumour recurrence, previously low biomarker levels exhibited a rapid and statistically significant elevation. Pre-treatment serum levels of Cyfra 21-1, as well as post-treatment, and follow-up levels of both oncomarkers in patients in remission, were identified as independent predictors of tumour-specific death.</p> Conclusion <p>Cyfra 21-1 and SCC Ag may serve as clinically valuable tumour markers in HNC, demonstrating significant prognostic relevance. Persistently elevated levels may indicate residual disease, while a marked increase in serial measurements is suggestive of tumour recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cyfra 21-1 and SCC Ag, Useful Oncomarkers in Head and Neck Cancer

  • 期刊论文

  • 发表日期：

    2025年11月4日

查看全文
  • Z. Horakova,
  • J. Zapletalova,
  • Richard Salzman

摘要

Objective

The study evaluates the clinical relevance of the serum biomarkers Cyfra 21-1 and SCC Ag in patients diagnosed with head and neck carcinoma (HNC).

Background

Unfortunately, no reliable circulating blood marker for HNC has yet been accepted for application in clinical practice.

Methods

We retrospectively analyzed serum concentrations of SCC Ag and Cyfra 21-1 in 326 patients, with measurements obtained pre-treatment, post-treatment, during follow-up, and at the time of recurrence.

Results

We confirmed a significant association between markers and tumour progression. The pre-treatment concentration dropped significantly after therapy in patients who achieved remission. We proposed SCC Ag and Cyfra 21-1 cut-off values of 2.0 ng/mL and 3.3 ng/mL for the selection of patients with residual disease. In cases of tumour recurrence, previously low biomarker levels exhibited a rapid and statistically significant elevation. Pre-treatment serum levels of Cyfra 21-1, as well as post-treatment, and follow-up levels of both oncomarkers in patients in remission, were identified as independent predictors of tumour-specific death.

Conclusion

Cyfra 21-1 and SCC Ag may serve as clinically valuable tumour markers in HNC, demonstrating significant prognostic relevance. Persistently elevated levels may indicate residual disease, while a marked increase in serial measurements is suggestive of tumour recurrence.